AIMC Topic: Drug Development

Clear Filters Showing 151 to 160 of 318 articles

A Convolutional Neural Network System to Discriminate Drug-Target Interactions.

IEEE/ACM transactions on computational biology and bioinformatics
Biological targets are most commonly proteins such as enzymes, ion channels, and receptors. They are anything within a living organism to bind with some other entities (like an endogenous ligand or a drug), resulting in change in their behaviors or f...

Artificial intelligence-driven phenotyping of zebrafish psychoactive drug responses.

Progress in neuro-psychopharmacology & biological psychiatry
Zebrafish (Danio rerio) are rapidly emerging in biomedicine as promising tools for disease modelling and drug discovery. The use of zebrafish for neuroscience research is also growing rapidly, necessitating novel reliable and unbiased methods of neur...

Logistic matrix factorisation and generative adversarial neural network-based method for predicting drug-target interactions.

Molecular diversity
Identifying drug-target protein association pairs is a prerequisite and a crucial task in drug discovery and development. Numerous computational models, based on different assumptions and algorithms, have been proposed as an alternative to the labori...

Future of machine learning in paediatrics.

Archives of disease in childhood
Machine learning (ML) is a branch of artificial intelligence (AI) that enables computers to learn without being explicitly programmed, through a combination of statistics and computer science. It encompasses a variety of techniques used to analyse an...

Recent trends in artificial intelligence-driven identification and development of anti-neurodegenerative therapeutic agents.

Molecular diversity
Neurological disorders affect various aspects of life. Finding drugs for the central nervous system is a very challenging and complex task due to the involvement of the blood-brain barrier, P-glycoprotein, and the drug's high attrition rates. The ava...

AI in drug development: a multidisciplinary perspective.

Molecular diversity
The introduction of a new drug to the commercial market follows a complex and long process that typically spans over several years and entails large monetary costs due to a high attrition rate. Because of this, there is an urgent need to improve this...

Artificial intelligence and the future of life sciences.

Drug discovery today
Over the past few decades, the number of health and 'omics-related data' generated and stored has grown exponentially. Patient information can be collected in real time and explored using various artificial intelligence (AI) tools in clinical trials;...

AI-based language models powering drug discovery and development.

Drug discovery today
The discovery and development of new medicines is expensive, time-consuming, and often inefficient, with many failures along the way. Powered by artificial intelligence (AI), language models (LMs) have changed the landscape of natural language proces...

Convolutional neural networks (CNNs): concepts and applications in pharmacogenomics.

Molecular diversity
Convolutional neural networks (CNNs) have been used to extract information from various datasets of different dimensions. This approach has led to accurate interpretations in several subfields of biological research, like pharmacogenomics, addressing...

Machine learning directed drug formulation development.

Advanced drug delivery reviews
Machine learning (ML) has enabled ground-breaking advances in the healthcare and pharmaceutical sectors, from improvements in cancer diagnosis, to the identification of novel drugs and drug targets as well as protein structure prediction. Drug formul...